Initiator Pharma A/S Stock | Price, Analyst Rating & Outlook for 2026

Initiator Pharma A/S

OM:INIT

kr 3,09

kr0,00 (0,00%)

3,09 kr

kr0,00 (0,00%)

End-of-day quote: 04/06/2026

Initiator Pharma A/S Stock Value

The analyst rating for OM:INIT is currently sf_No Opinion.

sf_No Opinion

Initiator Pharma A/S Company Info

EPS Growth 5Y

7,58%

Market Cap

kr0,21 B

Long-Term Debt

kr0,00 B

Quarterly earnings

05/08/2026

Dividend

kr0,00

Dividend Yield

0,00%

Founded

2016

Industry

Health Care

Country

Denmark

Website

Initiator Pharma A/S

ISIN Number

DK0060775872

Website

http://www.initiatorpharma.com

Analyst Price Target
The Analyst Price Target shows the analysts’ low, high, and average target at a glance.

kr9,52

208.09%

Last Update: 04/07/2026

Analysts: 2

Highest Price Target kr10,24

Average Price Target kr9,52

Lowest Price Target kr8,81

In the last five quarters, Initiator Pharma A/S’s Price Target has fallen from kr34,83 to kr15,41 - a -55,76% decrease. One analysts predict that Initiator Pharma A/S’s share price will increase in the coming year, reaching kr9,52. This would represent an increase of 208,09%.

Top growth stocks in the health care sector (5Y.)

What does Initiator Pharma A/S do?

Initiator Pharma A/S operates primarily in the pharmaceutical sector, focusing on the development of innovative therapeutic drugs for the treatment of erectile dysfunction (ED) and neuropathic pain. Business Segments The company operates through research and development, clinical trials, and commercialization of pharmaceutical products. Research and development Research and development are central to the company’s mission, featuring a rigorous approach to identifying promising drug candidate...

Initiator Pharma A/S operates primarily in the pharmaceutical sector, focusing on the development of innovative therapeutic drugs for the treatment of erectile dysfunction (ED) and neuropathic pain.

Business Segments

The company operates through research and development, clinical trials, and commercialization of pharmaceutical products.

Research and development

Research and development are central to the company’s mission, featuring a rigorous approach to identifying promising drug candidates. Leveraging cutting-edge biopharmaceutical science, the company develops potential therapies that particularly focus on conditions like erectile dysfunction, a prevalent issue affecting millions globally.

Clinical trials

This segment encompasses the gathering of data necessary for regulatory approvals, predominantly with the European Medicines Agency (EMA) and the US Food and Drug Administration (FDA), following stringent guidelines to maintain the integrity and credibility of results.

Commercialization of pharmaceutical products

This segment includes commercialization phase, where the company focuses on bringing its products to market. Here, Initiator Pharma employs marketing strategies to create awareness and ensure that healthcare providers and patients become privy to the advancements in its therapeutic offerings.

Business Strategy

The company’s overarching business strategy revolves around innovation-centric drug development, focusing on areas with significant unmet medical needs. With a core competency in biopharmaceutical research, the company seeks to invest significantly in developing differentiated products that not only outpace existing therapies in terms of efficacy but also exhibit favorable safety profiles.

Additionally, the company continuously monitors regulatory landscapes to remain compliant and streamline the approval processes for its drug candidates. This is crucial for maintaining a competitive edge in the market, ensuring that initiatives align with prevailing regulatory frameworks, and keeping abreast of any potential changes that could impact drug development timelines.

Products and Services

The company specializes in developing innovative drug candidates aimed at treating erectile dysfunction and neuropathic pain, with IPED2015 being the focal point of development. This drug is designed specifically for ED patients who do not respond to currently available oral therapies, thereby addressing a significant gap in the market.

The company's research and development manifests in the thoroughness of its clinical studies, which evaluate both the efficacy and safety of its product candidates. Each drug development process undergoes stringent phases including preclinical research, Phase I trials focusing on safety, Phase II trials examining efficacy, and Phase III trials confirming these findings across larger populations.

Beyond its drug candidates, the company maintains an intellectual property portfolio comprising patents and licenses essential for protecting its innovations. This is fundamental to ensuring that the company retains its competitive advantage in the biopharmaceutical sector.

The company is also engages in comprehensive clinical research services, which includes collaboration with various stakeholders involved in the drug development lifecycle. The company’s commitment to ensuring ethical practices and compliance in research underscores its dedication to not only advancing therapeutic options but also navigating the intricate landscape of pharmaceutical regulations effectively.

Geographical Markets Served

The company primarily focuses on the European market, given its proximity to regulatory bodies such as the EMA. However, with ongoing regulatory discussions, the company is also eyeing opportunities in the United States, leveraging the established pathways set by the FDA for drug approvals.

Seasonality

The company does not report any significant seasonal effects affecting its operations. The pharmaceutical sector typically observes continuous activity throughout the year, driven by ongoing research and clinical trials. Fluctuations may occur in specific research phases or data collection methods based on logistical factors, but overall, Initiator Pharma operates on a consistent year-round basis.

Customers

The company serves a diverse customer base, ranging from healthcare professionals such as doctors and specialists in urology and neurology, to healthcare institutions, including hospitals and clinics. Initiator Pharma also seeks engagement with pharmaceutical distributors and pharmacies for future commercial activities.

Modes of Sales and Marketing

The company currently engages in a modest approach toward marketing and distribution, given its focus on R&D. The company aims to establish a strategic marketing framework post-approval of its drug candidates.

The marketing strategy will likely involve direct engagement with healthcare professionals and leveraging educational initiatives to promote the benefits of its developed drugs. Interest in distribution channels points toward partnerships with established pharmaceutical firms to facilitate product availability in the market once regulatory approvals are obtained.

History

Initiator Pharma A/S was founded in 2016. The company was incorporated in 2016.

New support ticket

Explore

Initiator Pharma A/S Stock Value

Initiator Pharma A/S Company Info

Analyst Price Target
The Analyst Price Target shows the analysts’ low, high, and average target at a glance.

Top growth stocks in the health care sector (5Y.)

What does Initiator Pharma A/S do?

Offer & Services

Service & Collaboration

Company & Legal

New support ticket

Explore

Initiator Pharma A/S Stock Value

Initiator Pharma A/S Company Info

Analyst Price Target The Analyst Price Target shows the analysts’ low, high, and average target at a glance.

Top growth stocks in the health care sector (5Y.)

What does Initiator Pharma A/S do?

Offer & Services

Service & Collaboration

Company & Legal

Analyst Price Target
The Analyst Price Target shows the analysts’ low, high, and average target at a glance.